Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae

被引:25
作者
Jorgensen, JH
Swenson, JM
Tenover, FC
Barry, A
Ferraro, MJ
Murray, PR
Reller, LB
机构
[1] CTR DIS CONTROL & PREVENT,NOSOCOMIAL PATHOGENS LAB BRANCH,ATLANTA,GA 30333
[2] CLIN MICROBIOL INST INC,TUALATIN,OR 97062
[3] MASSACHUSETTS GEN HOSP,MICROBIOL LAB,BOSTON,MA 02114
[4] WASHINGTON UNIV,MED CTR,DEPT LAB MED,ST LOUIS,MO
[5] DUKE UNIV,MED CTR,CLIN MICROBIAL LAB,DURHAM,NC 27710
关键词
D O I
10.1128/JCM.34.11.2679-2684.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A six-laboratory collaborative study was conducted to develop MIC and zone diameter quality control limits and interpretive criteria for antimicrobial susceptibility testing of Streptococcus pneumoniae with azithromycin, clarithromycin, dirithromycin, and clindamycin. The MICs of all of the agents plus erythromycin for 302 clinical isolates of pneumococci that had been selected with an emphasis on resistant strains were determined by use of the National Committee for Clinical Laboratory Standards (NCCLS)-recommended broth microdilution procedure, The zone diameters of the isolates were also determined for the same agents except erythromycin by the NCCLS disk diffusion test procedure, Repeated testing of S. pneumoniae ATCC 49619 with different sources and lots of media and disks allowed development of MIC and zone diameter quality control ranges for these agents, Interpretive criteria for the MIC of azithromycin were established and were as follows: susceptible, less than or equal to 0.5 mu g/ml; intermediate, 1 mu g/ml; and resistant, greater than or equal to 2 mu g/ml. The interpretive criteria advocated for the MICs of clarithromycin and clindamycin were as follows: susceptible, less than or equal to 0.25 mu g/ml; intermediate, 0.5 mu g/ml; and resistant, greater than or equal to 1 mu g/ml. Comparison of MICs and disk diffusion zone diameters led to the development of interpretive criteria for the zone diameters for azithromycin, clarithromycin, and clindamycin that correlated well with these MIC breakpoints. Testing of this organism collection also led to the reestablishment of the erythromycin MIC breakpoints as being identical to those of clarithromycin, which resulted in equivalent cross-susceptibility and cross-resistance for the three macrolides that are currently marketed in the United States, Thus, the susceptibility of pneumococci to azithromycin and clarithromycin can be predicted accurately by testing only erythromycin in clinical laboratories, This recommendation, as well as the interpretive and quality control criteria that are described, have been accepted by NCCLS and are included in the latest NCCLS susceptibility testing guidelines.
引用
收藏
页码:2679 / 2684
页数:6
相关论文
共 18 条
  • [1] EMERGENCE OF DRUG-RESISTANT PNEUMOCOCCAL INFECTIONS IN THE UNITED-STATES
    BREIMAN, RF
    BUTLER, JC
    TENOVER, FC
    ELLIOTT, JA
    FACKLAM, RR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23): : 1831 - 1835
  • [2] THE ESCALATING PROBLEM OF ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE
    CHESNEY, PJ
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1992, 146 (08): : 912 - 916
  • [3] Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci
    Ednie, LM
    Visalli, MA
    Jacobs, MR
    Appelbaum, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) : 1950 - 1952
  • [4] FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607
  • [5] QUALITY-CONTROL LIMITS FOR AMPICILLIN, CARBENICILLIN, MEZLOCILLIN, AND PIPERACILLIN DISK DIFFUSION SUSCEPTIBILITY TESTS - A COLLABORATIVE STUDY
    GAVAN, TL
    JONES, RN
    BARRY, AL
    FUCHS, PC
    GERLACH, EH
    MATSEN, JM
    RELLER, LB
    THORNSBERRY, C
    THRUPP, LD
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1981, 14 (01) : 67 - 72
  • [6] THE PREVALENCE OF DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE IN ATLANTA
    HOFMANN, J
    CETRON, M
    FARLEY, MM
    BAUGHMAN, WS
    FACKLAM, RR
    ELLIOTT, JA
    DEAVER, KA
    BREIMAN, RF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (08) : 481 - 486
  • [7] TREATMENT AND DIAGNOSIS OF INFECTIONS CAUSED BY DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE
    JACOBS, MR
    [J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) : 119 - 127
  • [8] DEVELOPMENT OF INTERPRETIVE CRITERIA AND QUALITY-CONTROL LIMITS FOR BROTH MICRODILUTION AND DISK DIFFUSION ANTIMICROBIAL SUSCEPTIBILITY TESTING OF STREPTOCOCCUS-PNEUMONIAE
    JORGENSEN, JH
    SWENSON, JM
    TENOVER, FC
    FERRARO, MJ
    HINDLER, JA
    MURRAY, PR
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (10) : 2448 - 2459
  • [9] NEW DIRECTIONS FOR MACROLIDE ANTIBIOTICS - STRUCTURAL MODIFICATIONS AND INVITRO ACTIVITY
    KIRST, HA
    SIDES, GD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) : 1413 - 1418
  • [10] PNEUMOCOCCAL RESISTANCE TO ANTIBIOTICS
    KLUGMAN, KP
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1990, 3 (02) : 171 - 196